Evidence map›Paper›PMID 35617363›Full record

SynthesisPLoS medicine2022

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.

Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Anthony Hauser, Muhammad Irfanul Alam and 10 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. HLA-B*15:01-positive severe COVID-19 patients lack CD8Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Rethinking the evidence on COVID-19 in Africa.The Lancet. Infectious diseases · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 8 countries.

Diana Buitrago-GarciaInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-9761-206X
Aziz Mert IpekciInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0260-9691
Leonie HeronInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-3820-3343
Hira ImeriInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0412-1649
Lucia Araujo-ChaveronEHESP French School of Public Health, Paris and Rennes, France.ORCID 0000-0002-2110-6088
Ingrid Arevalo-RodriguezClinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER of Epidemiology and Public Health, Madrid, Spain.ORCID 0000-0002-7326-4504
Agustín CiapponiInstituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.ORCID 0000-0001-5142-6122
Muge CevikDivision of Infection and Global Health Research, School of Medicine, University of St. Andrews, Fife, Scotland, United Kingdom.ORCID 0000-0003-1133-3874
Anthony HauserInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-7221-1929
Muhammad Irfanul AlamEHESP French School of Public Health, Paris and Rennes, France.ORCID 0000-0002-8759-6585
Kaspar MeiliDepartment of Epidemiology and Global Health, Umeå University, Umeå, Sweden.ORCID 0000-0002-9889-4406
Eric A MeyerowitzDivision of Infectious Diseases, Montefiore Medical Center, Bronx, New York, New York, United States of America.ORCID 0000-0001-7954-6548
Nirmala PrajapatiUniversité Paris-Saclay, Paris, France.ORCID 0000-0001-7518-5968
Xueting QiuCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0001-6810-7304
Aaron RichtermanDivision of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-7920-7191
William Gildardo Robles-RodriguezFundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.ORCID 0000-0002-8383-6844
Shabnam ThapaManchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom.
Ivan ZhelyazkovUniversity of Sheffield, Sheffield, United Kingdom.ORCID 0000-0001-6320-7517
Georgia SalantiInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-3830-8508
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-4817-8986
University of Bern · CHCenter for Disease Dynamics, Economics & Policy · USCentro de Investigación Biomédica en Red · ESConsejo Nacional de Investigaciones Científicas y Técnicas · ARÉcole des Hautes Études en Santé Publique · FRFundación Universitaria de Ciencias de la Salud · COInstitut Pasteur · FRManchester Academic Health Science Centre · GBMontefiore Medical Center · USUmeå University · SEUniversité Paris-Saclay · FRUniversity of Pennsylvania · USUniversity of Sheffield · GBUniversity of St Andrews · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDebate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic? METHODS AND

findingsThe protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.

conclusionsBased on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2. REVIEW PROTOCOL: Open Science Framework (https://osf.io/9ewys/).

Indexed as

COVID-19Asymptomatic InfectionsHumansMass ScreeningProspective StudiesSARS-CoV-2

Identifiers

PMID35617363
PMCPMC9135333
OpenAlexW4281550495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.